Mast Therapeutics To Host Third Quarter 2016 Financial Results And Business Update Conference Call

SAN DIEGO, Nov. 1, 2016 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company will release its third quarter 2016 financial results on Tuesday, November 8, 2016. The Company will also host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss third quarter financial results and provide a general business update.

Interested parties may access the conference call by dialing (855) 239-3120 from the U.S. and (412) 542-4127 from outside the U.S. and should request the Mast Therapeutics, Inc. Third Quarter 2016 Conference Call. A live webcast of the conference call will be available online from the Investors section of Mast’s website at http://www.masttherapeutics.com/investors/events/. Replays of the webcast will be available on the Company’s website for 30 days and a telephone replay will be available through November 15, 2016 by dialing (877) 344-7529 from the U.S. and (412) 317-0088 from outside the U.S. and entering replay access code 10096120.

About Mast Therapeutics

Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company has two clinical-stage investigational new drugs, AIR001 and vepoloxamer. AIR001, a sodium nitrite solution for intermittent inhalation via nebulization, is in Phase 2 clinical development for the treatment of heart failure with preserved ejection fraction (HFpEF). More information can be found on the Company’s web site at www.masttherapeutics.com. Mast Therapeutics and the corporate logo are trademarks of Mast Therapeutics, Inc.

Mast Therapeutics, Inc. logo.

Logo - http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mast-therapeutics-to-host-third-quarter-2016-financial-results-and-business-update-conference-call-300355318.html

SOURCE Mast Therapeutics, Inc.

MORE ON THIS TOPIC